Figur8 Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Figur8 Inc. - overview
Established
2017
Location
Boston, MA, US
Primary Industry
Software
About
Founded in 2017 and based in Massachusetts, US, Figur8, Inc. develops a musculoskeletal (MSK) assessment tool designed to improve patient outcomes through precise measurements. The company was founded by its CEO, Nan-Wei Gong. In April 2026, Myant Inc.
acquired Figur8 Inc. from Phoenix Venture Partners, Taiwan Global Angels DigiTx Partners, Chloe Capital, Taiwania Capital, First Spark Ventures, P5 Health Ventures, E14 Fund, and Joyance Partners. Figur8 offers a bioMotion Assessment Platform (bMAP), which is a wearable technology that captures lab-grade biomechanics data on a patient's movement and helps patients recover faster and return to work by providing objective data on their progress. The data also helps identify potential muscle imbalances that could lead to future injuries.
bMAP captures detailed movement data, which translates to valuable insights into musculoskeletal health.
Current Investors
AllCloud BSD Ltd., E14 Fund, P5 Health Ventures
Primary Industry
Software
Sub Industries
Healthcare IT, Analytics & Performance Software, Medical Software
Website
www.figur8tech.com/
Verticals
Big Data, Cloud Computing, HealthTech, Wearables & Quantified Self
Company Stage
Acquired
Total Amount Raised
Subscriber access only
Figur8 Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.